Three Japanese randomized clinical trials evaluating tocilizumab monotherapy revealed consistent response of tocilizumab in RA patients. Remission rates exceeded 50% at 52 weeks and one study showed 43.3% achievement of ACR70. (Abstract #945).
The authors concluded that "targeted blockade of IL-6 signaling is a viable approach to the treatment of RA".
American College of Rheumatology Annual Congress (ACR)
mabthera-ra
Комментариев нет:
Отправить комментарий